A5007868555- Lung Cancer Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Advanced Radiotherapy Techniques
- Radiomics and Machine Learning in Medical Imaging
- Medical Imaging Techniques and Applications
- Neuroendocrine Tumor Research Advances
- Advances in Oncology and Radiotherapy
- Brain Metastases and Treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Advanced MRI Techniques and Applications
- Cancer Immunotherapy and Biomarkers
- Head and Neck Cancer Studies
- Radiation Therapy and Dosimetry
- Occupational and environmental lung diseases
- Pleural and Pulmonary Diseases
- Gastric Cancer Management and Outcomes
- Radiation Dose and Imaging
- Cancer survivorship and care
- Economic and Financial Impacts of Cancer
- Cardiac Imaging and Diagnostics
- Medical Imaging and Pathology Studies
- Colorectal Cancer Treatments and Studies
- Effects of Radiation Exposure
- Global Cancer Incidence and Screening
The Christie NHS Foundation Trust
2016-2025
University of Manchester
2016-2025
Cancer Research UK Manchester Institute
2016-2025
The Christie Hospital
2015-2024
National Health Service
2015-2024
Agence Régionale de Santé Nouvelle-Aquitaine
2023
Wolters Kluwer (Netherlands)
2023
European Organisation for Research and Treatment of Cancer
2007-2022
Manchester Academic Health Science Centre
2014-2022
University College London
2014-2021
An earlier analysis in this phase 3 trial showed that durvalumab significantly prolonged progression-free survival, as compared with placebo, among patients stage III, unresectable non-small-cell lung cancer (NSCLC) who did not have disease progression after concurrent chemoradiotherapy. Here we report the results for second primary end point of overall survival.We randomly assigned patients, a 2:1 ratio, to receive intravenously, at dose 10 mg per kilogram body weight, or matching placebo...
Primary lung cancer remains the most common malignancy after non-melanocytic skin cancer, and deaths from exceed those any other worldwide [1.IARC. Cancer Incidence, Mortality Prevalence Worldwide GLOBOCAN 2012. http://gco.iarc.fr/Google Scholar]. In 2012, was frequently diagnosed in males with an estimated 1.2 million incident cases worldwide. Among females, leading cause of death more developed countries second less The highest incidence is found Central/Eastern Europe Asia...
We conducted a randomized trial of prophylactic cranial irradiation in patients with extensive small-cell lung cancer who had response to chemotherapy.
A collaboration of multidisciplinary experts on the functional evaluation lung cancer patients has been facilitated by European Respiratory Society (ERS) and Thoracic Surgery (ESTS), in order to draw up recommendations provide clinicians with clear, up-to-date guidelines fitness for surgery chemo-radiotherapy. The subject was divided into different topics, which were then assigned at least two experts. authors searched literature according their own strategies, no central review being...
The phase III PACIFIC trial compared durvalumab with placebo in patients unresectable, stage non-small-cell lung cancer and no disease progression after concurrent chemoradiotherapy. Consolidation was associated significant improvements the primary end points of overall survival (OS; stratified hazard ratio [HR], 0.68; 95% CI, 0.53 to 0.87; P = .00251) progression-free (PFS [blinded independent central review; RECIST v1.1]; HR, 0.52; 0.42 0.65; < .0001), manageable safety. We report updated,...
BackgroundWhole brain radiotherapy (WBRT) and dexamethasone are widely used to treat metastases from non-small cell lung cancer (NSCLC), although there have been no randomised clinical trials showing that WBRT improves either quality of life or overall survival. Even after treatment with WBRT, the prognosis this patient group is poor. We aimed establish whether could be omitted without a significant effect on survival life.MethodsThe Quality Life Treatment for Brain Metastases (QUARTZ) study...
<b>Background:</b> Cancer registries recording all cases diagnosed in a well defined population represent the only way to assess real changes management of colon cancer at level. <b>Aims:</b> To determine trends over 23 year period treatment, stage diagnosis, and prognosis Côte-d9Or region, France. <b>Patients:</b> A total 3389 patients with between 1976 1998. <b>Methods:</b> Time clinical presentation, surgical chemotherapy postoperative mortality, survival were studied. non-conditional...
BackgroundMost patients with extensive stage small-cell lung cancer (ES-SCLC) who undergo chemotherapy, and prophylactic cranial irradiation, have persistent intrathoracic disease. We assessed thoracic radiotherapy for treatment of this patient group.MethodsWe did phase 3 randomised controlled trial at 42 hospitals: 16 in Netherlands, 22 the UK, three Norway, one Belgium. enrolled WHO performance score 0–2 confirmed ES-SCLC responded to chemotherapy. They were randomly assigned (1:1) receive...
A joint initiative by the British Thoracic Society and for Cardiothoracic Surgery in Great Britain Ireland was undertaken to update 2001 guidelines selection assessment of patients with lung cancer who can potentially be managed radical treatment.
BackgroundConcurrent chemoradiotherapy is the standard of care in limited-stage small-cell lung cancer, but optimal radiotherapy schedule and dose remains controversial. The aim this study was to establish a treatment regimen cancer.MethodsThe CONVERT trial an open-label, phase 3, randomised superiority trial. We enrolled adult patients (aged ≥18 years) who had cytologically or histologically confirmed Eastern Cooperative Oncology Group performance status 0–2, adequate pulmonary function....
IntroductionIn the phase 3 PACIFIC study of patients with unresectable stage III NSCLC without progression after chemoradiotherapy, durvalumab demonstrated significant improvements versus placebo in primary end points progression-free survival (hazard ratio [HR] = 0.52, 95% confidence interval [CI]: 0.42–65, p < 0.0001) and overall (OS) (HR 0.68, CI: 0.53–0.87, 0.00251), manageable safety no detrimental effect on patient-reported outcomes. Here, we report 3-year OS rates for all randomized...
IntroductionIn the Phase 3, placebo-controlled PACIFIC trial of patients with unresectable, stage III NSCLC without disease progression after concurrent chemoradiotherapy, consolidative durvalumab was associated significant improvements in primary end points overall survival (OS) (hazard ratio [HR] = 0.68; 95% confidence interval [CI]: 0.53–0.87; p 0.00251; data cutoff, March 22, 2018) and progression-free (PFS) (blinded independent central review; Response Evaluation Criteria Solid Tumors...